M. Seger

发表

Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial

J. Northrup, P. Kothare, M. Seger, 2012, BMC clinical pharmacology.

Pharmacokinetic‐pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis

J. Helterbrand, J. Dhainaut, M. Seger, 2002, Clinical pharmacology and therapeutics.

Pergolide: Multiple-Dose Pharmacokinetics in Patients with Mild to Moderate Parkinson Disease

Jaime Kulisevsky, Olivier Blin, Olivier Rascol, 2005, Clinical neuropharmacology.

Exenatide - pharmacokinetics, pharmacodynamics, safety and tolerability in patients ≥ 75 years of age with Type 2 diabetes.

P. Kothare, M. Seger, M. Mitchell, 2011, International journal of clinical pharmacology and therapeutics.

Intravenous administration of insulin lispro versus regular human insulin in patients with type 1 diabetes

M. Seger, JamesH. Anderson, Robert B. Johnson, 2000 .

Effect of age on the pharmacokinetics of duloxetine in women.

M. Heathman, M. Seger, S. Reddy, 2003, British journal of clinical pharmacology.

Inhibition of PKC β by Ruboxistaurin Does Not Enhance the Acute Blood Pressure Response to Nitroglycerin

M. Seger, C. Benson, J. Voelker, 2007, Clinical pharmacology and therapeutics.

Intramuscular injection of insulin lispro or soluble human insulin: pharmacokinetics and glucodynamics in Type 2 diabetes

J. Wyatt, M. Seger, J. Woodworth, 2001, Diabetic medicine : a journal of the British Diabetic Association.

Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points

Viswanath Devanarayan, Rocco L. Brunelle, Wendell C. Smith, 2017, The AAPS Journal.

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus

T. Heise, C. Kapitza, M. Seger, 2016, Diabetes, obesity & metabolism.

Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies

M. Seger, H. Linnebjerg, Maria M Ferreira, 2015, Diabetes Care.

Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro.

L. Heinemann, K. Rave, L. Nosek, 2005, Diabetes care.

Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL

M. Seger, H. Linnebjerg, S. Reddy, 2015, Clinical pharmacology in drug development.

AIR insulin capsules of different dose strengths may be combined to yield equivalent pharmacokinetics and glucodynamics.

L. Heinemann, K. Rave, B. Silverman, 2009, Diabetes technology & therapeutics.

Pharmacokinetic and glucodynamic comparisons of recombinant and animal-source glucagon after IV, IM, and SC injection in healthy volunteers.

M. Seger, J. Holcombe, R. Bowsher, 1999, Journal of pharmaceutical sciences.

Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro.

L. Heinemann, K. Rave, L. Nosek, 2005, Diabetes care.

Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies

M. Seger, H. Linnebjerg, Maria M Ferreira, 2015, Diabetes Care.